Efficacy of antiepileptic drugs in adults predicts efficacy in children A systematic review

Neurology

Volumn 79, Issue 14, 2012, Pages 1482-1489

  Pellock, John M ^a   Carman, Wendy J ^b   Thyagarajan, Veena ^b   Daniels, Tony ^c   Morris, Dexter L ^c   D'Cruz, O'Neill ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b OPTUM   (United States)

^c UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PLACEBO; TOPIRAMATE;

ADULT; AGE; ARTICLE; CHILD; DRUG EFFICACY; HUMAN; PARTIAL ONSET SEIZURE; PREDICTION; PRIMARY GENERALIZED TONIC CLONIC SEIZURE; PRIORITY JOURNAL; SEIZURE; TREATMENT OUTCOME;

EID: 84867499359     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31826d5ec0     Document Type: Article

References (16)

1. Rocchi F, Tomasi P. The development of medicines for children: Part of a series on pediatric pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni. Pharmacol Res 2011;64:169-175.
2. ICH Topic E 11 Clinical Investigation of Medicinal Products in the Paediatric Population: Note for Guidance on Clinical Investigation of Medicinal Products in the Paediatric Population (CPMP/ICH/2711/99). Available at: Www.ema.europa.eu/pdfs/human/ich/271199en.pdf. Accessed December 1, 2011.
3. Chiron C, Dulac O, Pons G. Antiepileptic drug development in children: Considerations for a revisited strategy. Drugs 2008;68:17-25.
4. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med 2009;6:e1000097.
5. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.
6. Cho MK, Bero LA. Instruments for assessing the quality of drug studies published in the medical literature. JAMA 1994;272:101-104.
7. Glauser TA, Dlugos DJ, Dodson WE, Grinspan A, Wang S, Wu SC. Topiramate monotherapy in newly diagnosed epilepsy in children and adolescents. J Child Neurol 2007; 22:693-699.
8. Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures: Topiramate YTC Study Group. Neurology 1999;52:1330-1337.
9. Pina-Garza JE, Nordli DR Jr, Rating D, Yang H, Schiemann-Delgado J, Duncan B. Adjunctive levetiracetam in infants and young children with refractory partialonset seizures. Epilepsia 2009;50:1141-1149.
10. Pina-Garza JE, Levisohn P, Gucuyener K, et al. Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months. Neurology 2008;70:2099-2108.
11. Novotny E, Renfroe B, Yardi N, et al. Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures. Neurology 2010;74:714-720.
12. FR specific requirements on content and format of labeling for human prescription drugs; revision of "pediatric use" subsection in the labeling. In: Department of Health and Human Services FaDAH, ed. Volume 59, Issue 238 Vol Final Rule. Office of the Federal Register, National Archives and Records Administration; 1994.
13. Regulation (EC) No 1901/2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/ 92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. In: Union TEPaTCotE, ed. Vol Final Rule. Official J Eur Union 2006.
14. Sheridan PH, Jacobs MP. The development of antiepileptic drugs for children: Report from the NIH workshop, Bethesda, Maryland, February 17-18, 1994. Epilepsy Res 1996;23:87-92.
15. Conclusions of the Paediatric Epilepsy Experts Group Meeting, London 1 September 2009. EMA/153272 Vol Final Rule: Human Medicines Development and Education; 2010. Available at: Http://www.ema.europa.eu/ema/index.jsp?curl- pages/news-and-events/events/2010/05/event-detail-000255.jsp&mid- WC0b01ac058004d5c3& jsenabled-true#. Accessed December 2, 2011.
16. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62: 1261-1273.